Detecting kidney issues in people with obesity and metabolic health variations
Official title: Early Detection of Renal Abnormalities in Metabolically Healthy and Unhealthy Weight Excess"
Run by Istituto Auxologico Italiano · NCT06338631 · Data updated 2026-11-12
This study is trying to see if being obese and having metabolic issues affect kidney health in adults aged 18 to 60, while also testing how diet changes might help.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Istituto Auxologico Italiano Academic / other |
| Locations | 2 sites (Milan and 1 other locations) |
| Status | Recruiting |
| Started | August 1, 2023 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | August 3, 2025 |
| Trial ID | NCT06338631 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 60 with a BMI of 25 kg/m2 or higher.
✕Probably not a fit
Patients with diabetes, renal disease, or systemic autoimmune diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between obesity, metabolic syndrome, and renal health. It focuses on understanding whether obesity and metabolic alterations independently increase the risk of renal damage. Participants aged 18 to 60 with a BMI of at least 25 kg/m2 will be observed, with a particular emphasis on differentiating between metabolically healthy obese individuals and those with metabolic complications. The study will involve dietary interventions to assess their impact on renal function.
Why it matters
Potential benefit: If successful, this study could lead to tailored treatment strategies for obesity-related renal health issues.
How similar studies have gone: While the relationship between obesity and renal health has been studied, this specific approach focusing on metabolic phenotypes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 60 years * BMI at least 25 kg/m2 Exclusion Criteria: * Pregnancy or breastfeeding * Diabetes mellitus * Renal disease * Systemic autoimmune diseases with possible renal involvement * Agonistic physical activity * Heart failure * Pharmacologcal treatment with RAAS-inhibitors, sartans, thiazide diuretics, loop diuretics * Urinary tract infection
Where it's running
-
Istituto Auxologico Italiano, Città Studi ICANS
Milan, Italy Recruiting -
Programma Infradipartimentale di Dietoterapia nel Trapianto e nell' Insufficienza Renale Cronica, DAI di Medicina Interna ad Indirizzo Specialistico, del Policlinico Federico II di Napoli
Naples, Italy Recruiting
Study contacts
- Study coordinator: Alberto Battezzati, Prof
- Email: a.battezzati@auxologico.it
- Phone: +390261911
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.